CRDL
Income statement / Annual
Last year (2024), Cardiol Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Cardiol Therapeutics Inc.'s net income was -$36.68 M.
See Cardiol Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$62.27 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$187.38 K
|
$162.23 K
|
$174.26 K
|
$180.17 K
|
$116.11 K
|
$91.49 K
|
$53.34 K
|
| Gross Profit |
$0.00
|
-$187.38 K
|
-$162.23 K
|
-$112.00 K
|
-$180.17 K
|
-$116.11 K
|
-$91.49 K
|
-$53.34 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
-1.8
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$14.01 M
|
$10.73 M
|
$13.99 M
|
$8.59 M
|
$8.25 M
|
$2.72 M
|
$1.53 M
|
$441.26 K
|
| General & Administrative Expenses |
$26.26 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.87 M
|
$1.10 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.26 M
|
$11.55 M
|
$16.34 M
|
$21.86 M
|
$7.81 M
|
$8.06 M
|
$5.87 M
|
$1.10 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$60.56 K
|
| Operating Expenses |
$40.28 M
|
$22.29 M
|
$30.33 M
|
$30.46 M
|
$16.06 M
|
$10.78 M
|
$7.49 M
|
$1.60 M
|
| Cost And Expenses |
$40.28 M
|
$22.47 M
|
$30.49 M
|
$30.63 M
|
$16.24 M
|
$10.89 M
|
$7.49 M
|
$1.60 M
|
| Interest Income |
$1.19 M
|
$2.04 M
|
$1.24 M
|
$106.00 K
|
$60.11 K
|
$245.42 K
|
$103.31 K
|
$6.12 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$621.00
|
$663.37 K
|
$60.56 K
|
| Depreciation & Amortization |
$162.11 K
|
$187.38 K
|
$162.23 K
|
$174.26 K
|
$180.17 K
|
$116.11 K
|
$91.49 K
|
$53.34 K
|
| EBITDA |
-$40.11 M |
-$21.04 M |
-$22.66 M |
-$24.84 M |
-$16.02 M |
-$10.44 M |
-$7.30 M |
-$1.50 M |
| EBITDA Ratio |
0
|
0
|
0
|
-398.91
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-490.92
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.60 M
|
$1.25 M
|
$7.68 M
|
$5.56 M
|
$38.87 K
|
$342.20 K
|
-$8.50 M
|
-$71.61 K
|
| Income Before Tax |
-$36.68 M
|
-$21.22 M
|
-$22.82 M
|
-$25.01 M
|
-$16.20 M
|
-$10.55 M
|
-$15.89 M
|
-$1.66 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-401.71
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$663.37 K
|
$60.56 K
|
| Net Income |
-$36.68 M
|
-$21.22 M
|
-$22.82 M
|
-$25.01 M
|
-$16.20 M
|
-$10.55 M
|
-$15.89 M
|
-$1.66 M
|
| Net Income Ratio |
0
|
0
|
0
|
-401.71
|
0
|
0
|
0
|
0
|
| EPS |
-0.51 |
-0.44 |
-0.49 |
-0.73 |
-0.69 |
-0.53 |
-0.66 |
-0.0731 |
| EPS Diluted |
-0.51 |
-0.44 |
-0.49 |
-0.73 |
-0.69 |
-0.53 |
-0.66 |
-0.0731 |
| Weighted Average Shares Out |
$71.57 M
|
$64.46 M
|
$62.51 M
|
$43.22 M
|
$29.86 M
|
$25.82 M
|
$24.20 M
|
$22.71 M
|
| Weighted Average Shares Out Diluted |
$71.57 M
|
$64.46 M
|
$62.51 M
|
$43.22 M
|
$29.86 M
|
$25.82 M
|
$24.20 M
|
$22.71 M
|
| Link |
|
|
|
|
|
|
|
|
